Last reviewed · How we verify
HRYZ-T101 TCR-T Cell
At a glance
| Generic name | HRYZ-T101 TCR-T Cell |
|---|---|
| Sponsor | HRYZ Biotech Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor (PHASE1)
- HRYZ-T101 Injection for HPV18 Positive Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRYZ-T101 TCR-T Cell CI brief — competitive landscape report
- HRYZ-T101 TCR-T Cell updates RSS · CI watch RSS
- HRYZ Biotech Co. portfolio CI